National Asset Management Inc. bought a new stake in Hologic, Inc. (NASDAQ:HOLX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 4,455 shares of the medical equipment provider’s stock, valued at approximately $203,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after purchasing an additional 1,200,825 shares during the period. State Street Corp boosted its holdings in Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after purchasing an additional 189,572 shares during the period. Capital World Investors purchased a new position in Hologic in the second quarter valued at $312,441,000. Victory Capital Management Inc. boosted its holdings in Hologic by 23.7% in the second quarter. Victory Capital Management Inc. now owns 5,012,352 shares of the medical equipment provider’s stock valued at $227,461,000 after purchasing an additional 961,528 shares during the period. Finally, Bank of Montreal Can boosted its holdings in Hologic by 6.6% in the second quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock valued at $155,123,000 after purchasing an additional 211,550 shares during the period. Hedge funds and other institutional investors own 96.38% of the company’s stock.

Shares of Hologic, Inc. (NASDAQ:HOLX) traded up 0.62% during trading on Wednesday, hitting $37.04. 102,695 shares of the stock traded hands. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80. The firm has a 50 day moving average price of $37.64 and a 200-day moving average price of $41.89. The company has a market cap of $10.39 billion, a PE ratio of 13.80 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the previous year, the firm posted $0.51 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. Analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on HOLX shares. Royal Bank Of Canada decreased their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Thursday, August 3rd. BidaskClub lowered Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Barclays PLC decreased their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $47.77.

In other news, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now owns 23,810 shares in the company, valued at approximately $955,257.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,775 shares of company stock worth $1,175,662. Insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/18/4455-shares-in-hologic-inc-holx-purchased-by-national-asset-management-inc.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.